Market Overview

Mitsui and Kirin Make a Strategic Investment in Thorne

Share:

Thorne today announced it has entered into an agreement for a joint
strategic investment with Mitsui & Co., Ltd. (Mitsui) and Kirin Holdings
Company, Limited (Kirin). The strategic investment will be used to help
expand Thorne's personalized health technology platform and products,
and to jointly grow their businesses in Asia.

The joint investment between Kirin and Mitsui aims to strengthen each
company's initiatives in global preventive health management and
wellness. This follows Mitsui's investment in Thorne late last year. The
Kirin Group owns Kyowa Hakko Kirin Group, which is a group of R&D-based
life science companies that contribute to the health and well-being of
people around the world by creating new value with special strengths in
biotechnologies.

Mitsui and Kirin now join Helsinn and Thorne's management team as
investors replacing the private equity firms WestView Capital Partners
and Tudor Ventures (now operating as Spring Lake Equity Partners) as
shareholders of Thorne.

"We are delighted to partner with Mitsui and Kirin because we all share
a philosophy that marries a strong dedication to science and research
with a disruptive approach of developing technologies to help consumers
take control of their health," said Paul Jacobson, Thorne's CEO. "This
partnership will help us to expedite our mission to become the global
market leader in prevention and wellness."

"We had been exploring investing in this space for quite some time, and
we chose Thorne because we believe it has a truly differentiated
business model which will help consumers gain health insights backed by
scientific evidence and lead to the development of innovative products
and services based on data," said Shinro Fujita, Director of Corporate
Strategy at Kirin.

"We continue to believe in Thorne's commitment to proving its products
and technology work through testing and research, which enables us to
develop a business model to provide consumers with a personalized
solution," said Masami Yokoyama, General Manager, NutriScience Division,
at Mitsui. "Through joint cooperation with Thorne and Kirin, we can
expand business in Japan and other global markets."

The announcement of the joint investment augments an already big year in
Thorne's strategy to expand into a health and technology company,
specializing in personalized consumer health. Earlier this year, the
company introduced five at-home health tests, and invested and partnered
with Drawbridge Health, the company many believe could become the leader
in convenient blood collection in both group and at-home settings
pending FDA clearance. Thorne also invested and co-founded a company
with Drs. Joel Dudley and Chris Mason to build a machine-learning based
company targeting actionable analytics and products for prevention and
wellness.

"We are proud of the success and growth of Thorne so far, lead by its
very professional management team, and warmly welcome Mitsui and Kirin
as new members of our investment team," stated Riccardo Braglia, CEO of
the Helsinn Group and Thorne board member.

"The Thorne team would like to thank WestView Capital Partners and Tudor
Venture for their support in helping us triple the size of the company
during their tenure as investors, and we look forward to substantial
growth in our new 270,000 square foot facility just outside Charleston,
South Carolina, with Mitsui, Kirin and Helsinn as our investors going
forward," stated Jacobson.

About Thorne

Thorne is a health and technology company that is disrupting prevention
and wellness. By combining dietary and lifestyle recommendations with
nutritional supplement intervention, Thorne is at the forefront of
personalized health. Thorne provides at-home biomarker tests to bring
the doctor to the consumer's home. By leveraging its sophisticated
analytical software, Thorne helps consumers uncover health insights and
confidently take action to optimize health outcomes. Based on individual
test results, Thorne's technology and team can deliver a personalized
plan on what to eat, how to exercise, and which Thorne supplements to
take.

Thorne is the only supplement manufacturer to collaborate with Mayo
Clinic on wellness research and content, and is the proud partner of a
number of U.S. National Teams, including U.S. Soccer, USA Hockey, and
USA Triathlon. Thorne is one of the fastest growing supplement
companies, and is rated the top practitioner-dispensed brand among 30-40
year-olds. For more information visit https://www.thorne.com/.

View Comments and Join the Discussion!